Genmab's dispute with its business partner over blockbuster drug Darzalex, the Johnson & Johnson-owned Janssen Biotech, may draw out.
"We can say very little. The timing is naturally uncertain, but you're summarizing it quite well. Yes, it may be decided in 2021, but it potentially could be in 2022," said Genmab CEO Jan van de Winkel on Wednesday at a teleconference.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.